ICARO BOSZCZOWSKI

(Fonte: Lattes)
Índice h a partir de 2011
12
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
PAHC, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/49 - Laboratório de Protozoologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Categoria: review ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 11 Citação(ões) na Scopus
    Characterization of epidemiological surveillance systems for healthcare-associated infections (HAI) in the world and challenges for Brazil
    (2014) NOGUEIRA JUNIOR, Cassimiro; MELLO, Debora Silva de; PADOVEZE, Maria Clara; BOSZCZOWSKI, Icaro; LEVIN, Anna Sara; LACERDA, Rubia Aparecida
    Surveillance systems for healthcare-associated infections (HAI) are essential for planning actions in prevention and control. Important models have been deployed in recent decades in different countries. This study aims to present the historical and operational characteristics of these systems and discuss the challenges for Brazil. Various models around the world have drawn on the experience of the United States, which pioneered this process. In Brazil, several initiatives have been launched, but the country still lacks a full national information system on HAI, thus indicating the need to promote action strategies, strengthen the role of States in communication between the Federal and local levels, pursue a national plan to organize surveillance teams with the necessary technological infrastructure, besides updating the relevant legislation for dealing with these challenges. Such measures are essential in the Brazilian context for the unified surveillance of HAI, aimed at healthcare safety and quality.
  • article 0 Citação(ões) na Scopus
    Clinical Equivalence between Generic Versus Branded Antibiotics: Systematic Review and Meta-Analysis
    (2023) COTIA, Andre; OLIVEIRA JUNIOR, Haliton Alves; MATUOKA, Jessica Y.; BOSZCZOWSKI, Icaro
    Regulatory authorities authorize the clinical use of generic drugs (GD) based on bioequivalence studies, which consist of the evaluation of pharmacokinetics after a single dose in vitro or in healthy individuals. There are few data on clinical equivalence between generic and branded antibiotics. Our aim was to synthesize and analyze the available evidence on the clinical efficacy and safety of generic antibiotics compared to their original formulations. A systematic review was performed on Medline (PubMed) and Embase and validated through Epistemonikos and Google Scholar. The last search was conducted on 30 June 2022. Meta-analyses of clinical cure and mortality outcomes were performed. One randomized clinical trial (RCT) and 10 non-randomized intervention studies were included. No differences in clinical cure were observed between groups in the meta-analysis (OR = 0.89, 95% CI [0.61-1.28]; I-2 = 70%, p = 0.005). No difference was observed between groups when considering the use of carbapenems for overall mortality (OR = 0.99, 95% CI [0.63-1.55]; I-2 = 78%) or death associated with infections (OR = 0.79, 95% CI [0.48-1.29], I-2 = 67%). Most of the studies were observational, and the duration of follow-up, the characteristics of the participants, and the sites of infections were heterogeneous. Due to the uncertainty of the evidence, it is not possible to contraindicate the use of generics, which is an important strategy to expand access.